Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena, Inc. reports developments as a biopharmaceutical company developing and commercializing medicines for central nervous system disorders. Its updates center on OLINVYK® (oliceridine) injection, a U.S.-approved intravenous opioid analgesic for acute pain in adults when alternatives are inadequate, and investigational CNS programs including TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for acute migraine, and TRV734 for maintenance treatment of opioid use disorder.
Recurring company news also covers financial results, cash resources, preclinical and formulation-study updates for TRV045, royalty-based financing arrangements tied to ex-U.S. OLINVYK economics, liability reductions, reverse stock splits, and trading-status changes following Nasdaq delisting and movement to OTC markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Trevena, Inc. (Nasdaq: TRVN) recently announced initial topline data from two real-world studies, VOLITION and ARTEMIS, focusing on their opioid, OLINVYK. In VOLITION, 52.2% of OLINVYK patients were GI complete responders, with over 90% feeling 'alert and calm' post-surgery. Meanwhile, ARTEMIS revealed a 1.6-day reduction in hospital stay (approximately 27%) compared to other IV opioids. The studies involved 203 patients in VOLITION and utilized EMR data from 96 OLINVYK and 457 matched patients in ARTEMIS. Initial results reflect positively on OLINVYK's efficacy in managing postoperative pain, though full respiratory outcome data is expected mid-2023.
Trevena Inc. (Nasdaq: TRVN) announced initial topline data from the OLINVYK studies, VOLITION and ARTEMIS, demonstrating positive gastrointestinal (GI) and cognitive outcomes. In the VOLITION study of 203 patients, the GI complete response rate was 52.2%, surpassing previous Phase 3 data. ARTEMIS indicated a statistically significant 1.6-day reduction in average hospital stay compared to other IV opioids. The company has $38.3 million in cash as of year-end 2022, sufficient to fund operations into Q4 2023. Additionally, two proof-of-concept studies for TRV045, a potential treatment for CNS disorders, are underway, with top-line data expected later this year.
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, will release its fourth quarter and full year 2022 financial results on March 30, 2023, before market open. A conference call and webcast will follow at 8:00 a.m. ET, featuring executives including Carrie Bourdow, CEO, and Barry Shin, CFO. Trevena, known for OLINVYK (oliceridine) injection for acute pain management, is also exploring innovative therapies for CNS disorders with investigational drugs like TRV045 for neuropathic pain, TRV250 for migraines, and TRV734 for opioid use disorder. The webcast will be accessible on the company's website.